Mr. Daniel Cowell is a Co-Founder and served as the Chief Executive Officer and a Board Member at Psyomics. He is a Board Member of Sentinal Oncology. He served as Chief Operating Officer at Horizon Discovery. He co-founded Pharmorphix, a specialist CRO in the area of solid form, which grew market share rapidly and was subsequently acquired by Sigma Aldrich in 2006. Following the sale of Pharmorphix he founded Hypoxium, a client focused CRO providing pre-clinical oncology research which grew its revenue at over 75% each year. He was appointed COO of Horizon Discovery following Hypoxium's acquisition in 2010. He holds a BS in Chemistry from University of Kent. He has spent the past 18 years leading the commercial and scientific direction of various UK based biotechnology companies, in fields ranging from oncology to translational genomics research.